Sonya Heltshe, PhD
Sonya Heltshe, PhD
Children's Title: Senior Biostatistician
Academic Title: Assistant Professor
Research Center: Center for Clinical and Translational Research
"Everyday I am able to apply math and think creatively to solve problems and improve the health of others. I also love the people I work with at Seattle Children's, who have endless motivation, compassion and integrity. Every year someone with cystic fibrosis (CF) comes to talk to us about how research has touched their lives and families; I am always humbled and moved by the honesty and openness of these children and adults living with CF."
I am a biostatistician working in clinical trials for Cystic Fibrosis.
I received my PhD in Biostatistics from the University of Colorado School Of Public Health in 2007 and completed a post-doc at the National Cancer Institute in 2009. As the Director of Biostatisics at the CF Foundations Therapeutic (CFFT) Development Network and Assistant Professor of Pediatrics at the University of Washington I am the statistician and principal investigator for many CF studies of all phases, from basic research to large scale epidemiologic studies. I have interests in statistical analyses and methodologies related to CF lung function, microbial diversity, proteomics, inflammatory markers, and predictive biomarkers. I am deeply committed to evidence based medicine and ethical research in pediatric disease.
Manuscripts in Refereed Journals
Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey BPseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
22944725 Journal of Cystic Fibrosis, 2012 Aug. : PMCID:PMC3696392
Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, Adam RJ, Carter S, Grogan B, Launspach JL, Donnelly SC, Gallagher CG, Bruce JE, Stoltz DA, Welsh MJ, Hoffman LR, McKone EF, Singh PKRestoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
28222269 American journal of respiratory and critical care medicine, 2017 June 15 : 195(12)1617-1628 PMCID:PMC5476912
Leung DH, Heltshe SL, Borowitz D, Gelfond D, Kloster M, Heubi JE, Stalvey M, Ramsey BW, Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.
28437538 JAMA pediatrics, 2017 June 1 : 171(6)546-554
Heltshe SL, Cogen J, Ramos KJ, Goss CHCystic Fibrosis: The Dawn of a New Therapeutic Era.
27710011 American journal of respiratory and critical care medicine, 2017 April 15 : 195(8)979-984 PMCID:PMC5422649
Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JLPregnancy among cystic fibrosis women in the era of CFTR modulators.
28190780 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017 Feb. 9 : PMCID:PMC5550358
Stalvey MS, Pace J, Niknian M, Higgins MN, Tarn V, Davis J, Heltshe SL, Rowe SMGrowth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.
28143919 Pediatrics, 2017 Feb. : 139(2) PMCID:PMC5260152
Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SDBiomarkers for cystic fibrosis drug development.
28215711 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016 Nov. : 15(6)714-723 PMCID:PMC5321565
Heltshe SL | Goss CH | Thompson V | Sagel SD | Sanders DB | Marshall BC | Flume PAShort-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
25911223 Thorax, 2015 April 24
Muhlebach MS | Heltshe SL | Popowitch EB | Miller MB | Thompson V | Kloster M | Ferkol T | Hoover WC | Schechter MS | Saiman L | the STAR-CF Study TeamMulticenter Observational Study on Factors and Outcomes Associated with Different MRSA Types in Children with Cystic Fibrosis.
25745825 Annals of the American Thoracic Society, 2015 March 6
Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM, GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development NetworkPseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor.
25425629 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015 March 1 : 60(5)703-12
Rowe SM | Heltshe SL | Gonska T | Donaldson SH | Borowitz D | Gelfond D | Sagel SD | Khan U | Mayer-Hamblett N | Van Dalfsen JM | Joseloff E | Ramsey BW | GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development NetworkClinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
24927234 American journal of respiratory and critical care medicine, 2014 July 15 : 190(2)175-84 PMCID:PMC4226057
DeBoer EM, Swiercz W, Heltshe SL, Anthony MM, Szefler P, Klein R, Strain J, Brody AS, Sagel SDAutomated CT scan scores of bronchiectasis and air trapping in cystic fibrosis.
Chest, 2014 March 1 : 145(3)593-603 PMCID:24114359
- Medical/Professional School
National Cancer Institute, Bethesda
University of Colorado School of Public Health, Aurora
- Research Description
Biostatistics, clinical trials, and translational research in Cystic Fibrosis and Pulmonology